Author/Authors :
Patil Prashant A. نويسنده Dhole Patil College of Engineering Wagholi, Pune , Giri Dinesh نويسنده Department of Paediatric Endocrinology, Alder Hey
Children’s Hospital, Liverpool, United Kingdom , Blair Joanne نويسنده Department of Paediatric Endocrinology, Alder Hey
Children’s Hospital, Liverpool, United Kingdom , Dharmaraj Poonam نويسنده Department of Paediatric Endocrinology, Alder Hey
Children’s Hospital, Liverpool, United Kingdom , Ramakrishnan Renuka نويسنده Department of Paediatric Endocrinology, Alder Hey
Children’s Hospital, Liverpool, United Kingdom , Das Urmi نويسنده Department of Paediatric Endocrinology, Alder Hey
Children’s Hospital, Liverpool, United Kingdom , Didi Mohammed نويسنده Department of Paediatric Endocrinology, Alder Hey
Children’s Hospital, Liverpool, United Kingdom , Senniappan Senthil نويسنده Department of Paediatric Endocrinology, Alder Hey
Children’s Hospital, Liverpool, United Kingdom
Abstract :
Background Constitutional delay of growth and puberty (CDGP) can
cause significant psychological distress in adolescent boys. Although
testosterone usage in this group has not been shown to affect the final
adult height, the effect on the first year height velocity has not been
widely reported. Objectives The aim is to determine whether testosterone
treatment improves the first year height velocity in boys with CDGP when
compared to boys with CDGP who go through puberty spontaneously Methods
Retrospective data from 23 adolescent boys with CDGP was analysed. Ten
out of 23 boys (43%) received testosterone injection (testosterone
enanthate, 125 mg), once every 6 weeks for 3 doses in total. Both the
groups (treated and untreated) had their height, bone age and testicular
volume measured at the baseline, The height velocity and final predicted
adult height were compared at the end of one year between both the
groups. Results In the testosterone-untreated group, the mean (± SD)
chronological age, bone age, height standard deviation scores (SDS) and
testicular volume were 14.3 years (± 0.3),12.1 years (± 1.6), -1.9 (±
0.8) and 4.7 mL (± 1.1) respectively. Within the testosterone-treated
group the mean (± SD) chronological age, bone age, height SDS and
testicular volume at presentation were 14.4 years (± 0.4), 11 years (±
1.6), -2.1 SD(± 0.6) and 4.5 mL (± 1.2) respectively. The mean age of
treatment with testosterone was 14.4 years (± 0.44). The mean height
velocity one year after treatment was 8.4 cm/year (± 1.7) in the
testosterone treated group when compared to 6.1 cm/year (± 2.1) in the
patients who did not receive treatment (P = 0.01). There was no
significant difference in the final predicted height between the 2
groups (P = 0.15). Conclusions Testosterone therapy improves the first
year height velocity in boys with CDGP, without influencing their final
predicted height.